| Identification | Back Directory | [Name]
Benzeneacetic acid, α,α-diphenyl-, coMpd. with (α1R)-α1-[[[6-[2-[(2,6-dichlorophenyl)Methoxy]ethoxy]hexyl]aMino]Methyl]-4-hydroxy-1,3-benzenediMethanol (1:1) | [CAS]
503070-58-4 | [Synonyms]
GW642444M
GW-642444M
GW 642444M
GW642444M Trifenate
Vilanterol Trifenate
GW642444 (trifenatate)
vilanterol trifenatate
Vilanterol triphenylacetate
Vilanterol Trifenatate (API)
GW642444M; GW 642444M; GW-642444M
Pharmaceuticals Chemical Vilanterol Trifenatate Powder
4-[(R)-2-[[6-[2-(2,6-Dichlorobenzyloxy)ethoxy]hexyl]amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol triphenylacetate
(R)-4-(2-((6-(2-((2,6-dichlorobenzyl)oxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenyl 2,2,2-triphenylacetate
Benzeneacetic acid, α,α-diphenyl-, coMpd. with (α1R)-α1-6-2-(2,6-dichlorophenyl)MethoxyethoxyhexylaMinoMethyl-4-hydroxy-1,3-benzenediMethanol (1
Benzeneacetic acid, α,α-diphenyl-, coMpd. with (α1R)-α1-[[[6-[2-[(2,6-dichlorophenyl)Methoxy]ethoxy]hexyl]aMino]Methyl]-4-hydroxy-1,3-benzenediMethanol (1
Benzeneacetic acid, α,α-diphenyl-, coMpd. with (α1R)-α1-[[[6-[2-[(2,6-dichlorophenyl)Methoxy]ethoxy]hexyl]aMino]Methyl]-4-hydroxy-1,3-benzenediMethanol (1:1) | [EINECS(EC#)]
638-763-2 | [Molecular Formula]
C24H33Cl2NO5.C20H16O2 | [MDL Number]
MFCD28978327 | [MOL File]
503070-58-4.mol | [Molecular Weight]
774.78 |
| Chemical Properties | Back Directory | [Melting point ]
131.9-134.2℃ | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Dichloromethane (Slightly), Methanol (Slightly) | [form ]
Solid | [color ]
White to Off-White | [Stability:]
Hygroscopic | [InChIKey]
KLOLZALDXGTNQE-NETKZVBLNA-N | [SMILES]
C(C1C=CC=CC=1)(C1C=CC=CC=1)(C1C=CC=CC=1)C(=O)O.[C@H](C1C=CC(O)=C(CO)C=1)(O)CNCCCCCCOCCOCC1C(=CC=CC=1Cl)Cl |&1:22,r| |
| Hazard Information | Back Directory | [Chemical Properties]
Vilanterol trifenatate is a white powder with a molecular weight of 774.8, and the empirical formula is C24H33Cl2NO5.C20H16O2. It insoluble in water and slightly soluble in methanol, ethanol, acetonitrile and propan-2-ol. It is slightly hygroscopic. It is provided in a micronized form. | [Uses]
Vilanterol Trifenatate is a long-acting β2 adrenergic receptor Agonist with alonger than 24-hour activity in humans, and is being developed to be used in combination with FF. It is also highly selective for the β2-receptor, with over 1000-fold greater selectivity compared to β1-receptors. It demonstrates prolonged bronchodilation in subjects with asthma and COPD. | [Definition]
ChEBI: Vilanterol Trifenatate is a triphenylacetate salt obtained by combining vilanterol with one equivalent of triphenylacetic acid. Used in combination with fluticasone furoate for treatment of bronchospasm associated with chronic obstructive pulmonary disease. It has a role as a beta-adrenergic agonist and a bronchodilator agent. It contains a vilanterol(1+). | [Preparation]
Vilanterol trifenatate is synthesized by incorporation of an oxygen atom at the homobenzylic position of the right-hand side phenyl ring of (R)-salmeterol and has suitable chemical properties for inhaled administration. The combination in fluticasone furoate (FF) and vilanterol trifenatate (VI) in a single inhaler is the first once daily combination available on the market for the treatment of stable COPD. | [Biological Activity]
vilanterol trifenatate is a novel and selective agonist of β2-ar with a pec50 value of 10.37±0.05 [1].vilanterol trifenatate is a novel long-acting β2-ar agonist (laba) with 24h activity in development for inhaled once daily treatment. in the radioligand binding studies, vilanterol trifenatate has shown the binding affinity in the one-affinity site model with pkd values of 9.44±0.07 and 10.82±0.12 in the presence gpp(nh)p and absence gpp(nh)p, respectively. in dissociation studies, vilanterol trifenatate has been reported to bind from the β2-ar with a dissociation t1/2 value of 3.5 min in the presence of gpp(nh)p. vilanterol trifenatate has been found to have a good selectivity for β2-ar over the other β-ar receptor subtypes(β1and β3) with pec50 values of 10.37±0.05, 6.98±0.03 and 7.36±0.03, respectively. vilanterol trifenatate has exhibited at least 1000-fold selectivity over both β1-and β3-ar subtypes [1]. | [storage]
Store at -20°C | [Dosage]
The recommended and maximum dose is one inhalation of vilanterol trifenatate 25 micrograms once daily either morning or evening but at the same time every day. | [Mode of action]
Vilanterol Trifenatate is a selective long-acting beta2-receptor agonist (also referred to as a LABA). The pharmacologic effects of beta2-adrenoceptor agonist drugs, including vilanterol trifenatate, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyses the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. | [References]
[1] slack rj1, barrett vj, morrison vs, sturton rg, emmons aj, ford aj, knowles rg.in vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.j pharmacol exp ther. 2013 jan; 344(1):218-30. |
|
|